U.S. FDA approves first fecal microbiota product
On November 30, 2022, the U.S. Food and Drug Administration (FDA) approved FerringPharma's fecal microbiota product, Rebyota, for the treatment of rCDI, the first time the FDA has approved a fecal microbiota product.
Rebyota is approved for the prevention of recurrent recurrent Clostridioides difficile infection (CDI) in patients 18 years of age and older. The drug is intended for patients 18 years of age and older with recurrent CDI who have completed treatment with antibiotic therapy and is administered as a single rectal dose. The application for Rebyota has been designated and approved as a Breakthrough Therapy, Expedited Approval, and Orphan Drug Application.
This approval represents a step forward in the treatment of patients with recurrent CDI," said Peter Marks of the FDA's Center for Biologics Evaluation and Research (CBER).
In this study, approximately 1,000 subjects received Rebyota, and the estimated success rate in preventing recurrent CDI was significantly higher in the Rebyota group (70.6%) than in the placebo group (57.5%).
THE FIRST FDA APPROVAL OF A FECAL MICROBIOTA PRODUCT IS EXPECTED TO ACCELERATE THE DEVELOPMENT OF FMT AS A DRUG.
FDA News Release
[FDA Approves First Fecal Microbiota Product] 30.11.2022
Felling Press Release
[Felling Receives U.S. FDA Approval for
REBYOTA® (Fecal Microbiota, live-jslm)
- Novel First-in-Class Microbiota-Based Live Biopharmaceutical -] 2022.12.09
Other articles on announcements and activity reports
September 22, 2023
The 7th Annual Conference
The 7th Annual Conference was held on September 17 (Sun.). The conference was held simultaneously at the venue and online, and was attended by many people from medical professionals, general companies, research institutions, patients, and the general public. Thanks to all of you, the conference was successfully held [...].
April 20, 2023
A clinical study of a new FMT method using hydrogen nanobubble water (NanoGAS® water) without antimicrobial agents has been initiated.
Clinical Study on the Efficacy and Safety of a Novel Fecal Microbiota Transplantation Method for Autism Spectrum Disorders A clinical study by physicians and others affiliated with our research group has been initiated. The study is available on the jRCT (Japanese Research Reporting and Clinical Trial Submission System) at https:// [...].
March 20, 2023
Patented (Symbiosis, Inc.)
We are pleased to announce that we have been granted a patent for "Bioinduction Aid Solvent and Method of Using the Same," for which an application was filed by Symbiosis, Inc. Patent Information [Patent No.] Patent No. 7231799 [Title of the Invention] "Bioinduction Aid Solvent and Method of Using the Same" [...